

# **Guide to the quality and safety of tissues and cells for human application**

2<sup>nd</sup> Edition

The *Guide to the quality and safety of tissues and cells for human application* is published by the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM).

All rights conferred by virtue of the International Copyright Convention are specifically reserved to the Council of Europe and any reproduction or translation requires the written consent of the publisher.

Director of the publication: Dr S. Keitel

Page layout and cover: EDQM

Cover photo: © Fotolia – everythingpossible

European Directorate for the Quality  
of Medicines & HealthCare (EDQM)

Council of Europe

7, allée Kastner

CS 30026

F-67081 STRASBOURG

FRANCE

Website: [www.edqm.eu](http://www.edqm.eu)

To order: [www.edqm.eu/store](http://www.edqm.eu/store)

FAQs & EDQM HelpDesk: [www.edqm.eu/hd](http://www.edqm.eu/hd)

ISBN 978-92-871-8126-8

© Council of Europe, 2015

Printed at the Council of Europe



Partially funded by the European Union  
in the framework of the Health Programme  
2008-2013

## Foreword

Founded in 1949, the Council of Europe is the oldest and largest of all European institutions and now numbers 47 member states.<sup>1</sup> One of its founding principles is that of increasing co-operation between member states to improve the quality of life for all Europeans. Within this context of intergovernmental co-operation in the field of health, the Council of Europe has consistently selected ethical problems for study. One of the most important of these ethical issues relates to the non-commercialisation of human substances: blood, organs, tissues and cells.

Transplantation activities at the Council of Europe are co-ordinated by the European Directorate for the Quality of Medicines & Health-Care (EDQM). This Directorate is a key European organisation involved in the harmonisation, co-ordination, standardisation,

---

<sup>1</sup> Albania, Andorra, Armenia, Austria, Azerbaijan, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Republic of Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, San Marino, Serbia, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, 'the former Yugoslav Republic of Macedonia', Turkey, Ukraine, United Kingdom.

regulation and quality control of medicines, blood transfusion, organ transplantation, pharmaceuticals, pharmaceutical care, consumer health, cosmetics and food packaging.

Transplant medicine and transplantation have progressed during recent decades in a way nobody would have imagined in the preceding years. As with organs, the demand for some transplantable tissues and cells far outweighs the available supply. This has important consequences because human tissues and cells for human application can save lives or restore essential functions. However, as with all transplanted material of human origin, they carry risks of disease transmission that must be controlled by application of scrupulous donor selection and testing criteria, as well as ensuring that comprehensive quality systems are in place.

The first edition of the *Guide to the quality and safety of tissues and cells for human application* was published in 2013. It collated updated information to provide transplant professionals with a useful overview of the most recent advances in the field as well as technical guidance on ensuring the safety and quality of human tissues and cells applied to patients. To increase safety for recipients of human tissues and cells, it is essential that professionals involved in identifying potential donors, transplant co-ordinators managing the process of donation after death, bone marrow and cord blood collection centres, tissue establishments processing and storing tissues and cells, and inspectors auditing any of the establishments and organisations responsible for human application have easy access to this information. This Guide aims to support professionals on a practical level and improve the rate of successful and safe clinical application of tissues and cells.

This Guide contains the instructions considered to be the ‘minimum standards’ that align with relevant European Union (EU) Directives in the field, and provides assistance for those states outside the EU that consider adopting the EU requirements in their legislation. These standards state ‘what must be done’. However, this Guide goes beyond these standards by providing additional technical advice, based heavily on good manufacturing practice (GMP) guidelines and on

best practices consistent with current scientific knowledge and expert opinion. It describes background information that should be considered in forming policy decisions, as well as in educational initiatives. This additional information explains the ‘why and how’. It also refers to developments that have yet to be incorporated in EU Directives, thereby providing advance information and recommendations regarding technical developments in the field.

Whereas tissue establishments in EU member states are required to comply with legislation derived from EU Directives, this Guide is intended to facilitate ongoing improvements in the donation, procurement, testing, processing, preservation, storage and distribution of tissues and cells through education and provision of non-binding recommendations for EU member states and also for non-EU European countries. At any given time, implementation of these recommendations among member states and individual tissue establishments may vary, and alternative procedures, practices and standards of equivalent safety and quality may be in place.

This Guide has been divided into two parts. Part A contains general requirements applicable to all establishments involved in the donation, procurement, testing, processing, preservation, storage and distribution of tissues and cells that are not manipulated extensively. Part B contains specific guidelines and requirements for the different tissue and/or cell types. The general guidelines of Part A also apply to tissues and cells that have not been mentioned specifically in Part B of the present edition.

In this second edition, many chapters have been improved, and new and important chapters have been added. Most importantly, the field of assisted reproduction is now addressed in detail in Chapter 25 and the topic of fertility preservation is introduced in Chapter 26. The assisted reproduction field is regulated in the EU together with other types of tissues and cells that are applied to patients by Directive 2004/23/EC and its associated technical directives. This field is also included by the World Health Organization (WHO) in its definition of Medical Products of Human Origin (MPHO), which shares a

common need for robust ethical oversight and for safety and quality measures (requirements associated with their common origin in a human donor). A new working group was established with representatives from authorities and the European Society for Human Reproduction and Embryology (ESHRE) to develop these chapters and to carry out an extensive review of the chapters of Part A to ensure that they adequately address this field. It is notable that the generic chapters on topics such as quality management and donor consent, for instance, required minimal adaptation to address the field of assisted reproduction. The specific aspects of the field are addressed in detail in Chapter 25 in Part B. As a consequence of the inclusion of assisted reproduction in the guide, Chapter 1 (Introduction) has been updated to include important ethical principles that must be respected in the human assisted fertility field.

A very significant enhancement to the Guide has been the development of a chapter (new Chapter 8) dedicated to the principles of microbiological testing of tissue and cell preparations and their processing environments. Development of Chapter 8 was challenging because in the past the topic has been considered in a disjointed manner, with stakeholders involved in the collection or processing of tissues and cells developing their own principles and practices, and regulatory requirements providing minimal technical detail. The authors of this Guide have worked to achieve a practical and scientifically sound approach to this topic by bringing their prior knowledge and experience of microbiological testing in the field of pharmaceutical manufacture to the discussion. We believe that Chapter 8 is a key addition to this edition, recommending (among other features) the testing methods to be applied in the laboratory and, most importantly, outlining the principles that underpin validation of those methods. Some questions were not fully resolved and will be developed further in future editions.

As the fields of donation and transplantation of tissues and cells evolve, new and more sophisticated technologies will provide opportunities to make tissues and cells safer, or their engraftment more effective. Depending on the degree of complexity of the processing or

the manner in which the tissues or cells are applied to the recipient, some of these tissues and cells are classified in the EU as ‘medicinal products’. In many non-EU European countries, this differentiation is not made at a regulatory level, or there is no regulation of the field. Even in EU member states, many tissue establishments are working with tissues or cells that are subsequently sent for manufacture as Advanced Therapy Medicinal Products (ATMP) or are manufacturing those products themselves under the ‘hospital exemption’ allowed by the Regulations on ATMP. Hence, new chapters have been introduced in the Guide to address this field of cell therapy in particular. Chapter 20 provides a didactic overview of the field by describing the different ways in which cells can be expanded, modified or combined with scaffolds to replace damaged or diseased tissues in the recipient. Chapter 22 describes several types of cells (apart from haematopoietic stem cells) that are rapidly becoming important tools in the fight against disease. These chapters do not attempt to classify such cells or tissues under EU or other regulatory definitions. Instead, they inform readers that they must be fully aware of the regulatory classification of the tissues and cells they are working with, follow GMP, and have a marketing authorisation where they are classified as medicinal products. Chapters of this Guide that relate to recruitment and consent of donors, evaluation and testing of donors, as well as procurement of tissues and cells apply in full to the tissues and cells donated for any clinical application.

A new ‘place-holder’, Chapter 23, has been added and provides general principles to be considered if banking adipose tissue, an activity that is showing promise for patients with scarring due to tumour removal or burns. Chapter 24 (Other substances of human origin) introduces several other substances obtained from humans for autologous or allogeneic use: human breast milk, faecal microbiota, teeth/dental pulp, platelet-rich plasma, platelet-rich fibrin and serum eye drops. The regulatory status of these substances in most countries is unclear, but their human origin and the processes applied to procure, process and preserve them are analogous to those that apply for the tissues and cells described in this Guide (particularly in Part A). Hence, they

have been added as a means of providing a generic quality and safety framework for healthcare professionals treating patients with these substances.

Other enhancements to the Guide have been division of the former chapter on identification of potential donors, consent and evaluation into two new, more comprehensive chapters: Chapter 3 (Recruitment of potential donors) and Chapter 4 (Donor evaluation). Chapter 5 (Donor testing) now includes a detailed section that describes principles for validation of screening assays for infectious diseases used for testing blood from deceased donors, and considers differences in test results obtained by various types of testing laboratories (hospital-based versus reference laboratory). Chapter 7 (Processing and storage) has been updated to cover more detailed instructions on the requirements of processing facilities as well as monitoring of such facilities (viable and non-viable particles). The text has also been bolstered with more detailed information on the requirements of the cleaning of facilities, storage and exceptional release. Chapters 9 (Distribution and import/export) and 13 (Traceability) include the new EU requirements for the import and coding of tissues and cells. Finally, all of the chapters have been revised thoroughly to update their contents with the most recent advances in the field.

Throughout this Guide, use of the word ‘must’ indicates mandatory compliance in alignment with EU Directives, whereas use of the word ‘should’ indicates recommended compliance in accordance with good practice. In addition, unless otherwise stated, the guidelines apply only to human tissues and cells intended for transplantation or clinical use (including insemination and fertilisation). Tissues and cells used for ‘basic’ research do not fall under the scope of the present Guide.

Two working groups have contributed to the elaboration of this Guide. Working group TO055 helped to update the first edition and their work was co-ordinated by Deirdre Fehily (Italy) and Esteve Trias (European Association of Tissue Banks [EATB]). Working group TO056 drafted the new chapters on ‘Assisted reproductive technolo-



gies' and 'Fertility preservation', and their work was co-ordinated by Anna Veiga (ESHRE) and Carlos Plancha (Portugal). Names of the experts that participated in both groups can be found in Appendix 14 of the Guide. These experts contributed to different aspects of the book and did a tremendous job in reviewing the literature and extracting knowledge from numerous international guidelines, collaborative projects and diverse publications and Internet websites with the aim of ensuring accessibility to all this information.

In addition, other experts contributed in the discussions on various parts of this Guide and should be acknowledged:

Anna Vilarrodona Serrat (Spain)  
Alan Kitchen (United Kingdom)  
Alexandra Karström (Sweden)  
Anders Lindahl (Sweden)  
Anne Rosser (United Kingdom)  
Branka Golubic Cepulic (Croatia)  
Bronwen Shaw (World Marrow Donors Association)  
Carl Jorns (Sweden)  
Christian Chabanon (France)  
Dagmar Schilling-Leiß (Germany)  
Elba Agustí i Rovira (Spain)  
Etienne van den Abbeel (Belgium)  
Elisa Pianigiani (Italy)  
Evi Petrisli (Italy)  
Fredrik Huss (Sweden)  
Gilbert Verbeken (Belgium)  
Iván Miranda Álvarez-Pickman (Spain)  
Izabela Uhrynowska-Tyszkiewicz (Poland)  
Jaime Tabera Fernández (Spain)  
Juan Bueren (Spain)  
Jan-Oliver Karo (Germany)  
Jürgen Scherer (Germany)  
Katarina Le Blanc (Sweden)  
Lydia Foeken (World Marrow Donors Association)  
Marco Straccia (Spain)

Marjo Schutskoff-Jääskeläinen (Finland)

Nadine Ectors (Belgium)

Olle Korsgren (Sweden)

Òscar Fariñas Barbera (Spain)

Phil Sanders (Spain)

Ramón Farre (Spain)

Raquel Martín Ibáñez (Spain)

Ricardo Pedro Casaroli-Marano (Spain)

Rolf Kiessling (Sweden)

Soeren Ziebe (Denmark)

Ute Sicker (Germany)

Utta Schurig (Germany)

We would also like to thank all the experts that participated in the open consultation and provided extremely useful comments and suggestions.

Special thanks should be given to the European Commission, in particular to Ioana-Raluca Siska, who ensured the current text remained aligned with EU Directives and who made available the results from EU-funded projects.

Several professional associations, in particular the American Association of Tissue Banks (AATB), EATB, ESHRE and the European Society for Blood and Marrow Transplantation (EBMT) should also be thanked for sharing their experience and knowledge.

The drafting and publication of the second edition of the Guide was co-ordinated by Marta López Fraga (Scientific Officer in charge of the Council of Europe European Committee on Organ Transplantation [CD-P-TO]) with the assistance of Ahlem Sanchez, David Crowe and Isabelle Vernay. An extended thank you should also be given to Karl-Heinz Buchheit, Head of the Department of Biological Standardisation, OMCL Network & HealthCare (DBO), and Susanne Keitel, Director of the EDQM.

The entire project has been an exceptional combined effort, with extensive discussions dedicated towards the common goal of increasing the safety, efficacy and quality of donation of tissues and cells, as well

as the testing, processing and storage for clinical application of tissues and cells. The final result is this Guide, which constitutes a common European standard, based on the long-standing expertise and knowledge of the EDQM.



# Contents

<b>Foreword</b> .....	3
<b>PART A. GENERAL REQUIREMENTS</b> .....	33
<b>Chapter 1 Introduction</b> .....	35
1.1. Scope and purpose of this guide .....	35
1.2. Brief history of tissue and cell transplantation and banking ..	39
1.3. European Committee on Organ Transplantation, the European Directorate for the Quality of Medicines & HealthCare and the Council of Europe .....	43
1.4. Recommendations and regulations in the field .....	44
1.4.1. Council of Europe .....	44
1.4.2. World Health Organization .....	48
1.4.3. European Union .....	50
1.5. Benefits and risks of human application of tissues and cells ..	55
1.6. Process of donation of tissues and cells and application in humans .....	58
1.7. Tissue banks, biobanks and tissue establishments .....	62
1.8. Quality and safety .....	63
1.9. Ethical issues .....	65
1.9.1. Consent .....	66
1.9.2. Conflicts of interest .....	68
1.9.3. Financial aspects of donation and transplantation .....	68
1.9.4. Equitable access to transplantation or to assisted reproductive technology treatment .....	70

1.9.5. Equity in donation . . . . .	72
1.9.6. Anonymity . . . . .	73
1.9.7. Transparency. . . . .	74
<b>1.10. References . . . . .</b>	<b>75</b>

**Chapter 2 Quality management, risk management and validation. . . . .**

<b>2.1. Introduction . . . . .</b>	<b>85</b>
<b>2.2. Applying quality management in donation and banking of tissues and cells. . . . .</b>	<b>87</b>
<b>2.3. Personnel and organisation . . . . .</b>	<b>88</b>
2.3.1. Key personnel . . . . .	88
2.3.2. Training. . . . .	88
2.3.3. Safety issues for healthcare personnel working with tissues and cells for human application . . . . .	89
2.3.4. Safety issues for tissues or cells handled by personnel with bacterial or viral infections . . . . .	89
<b>2.4. Premises, equipment and materials. . . . .</b>	<b>89</b>
2.4.1. Premises . . . . .	90
2.4.2. Equipment . . . . .	91
2.4.3. Materials. . . . .	93
<b>2.5. Contractual arrangements. . . . .</b>	<b>94</b>
<b>2.6. Documentation and record-keeping . . . . .</b>	<b>96</b>
<b>2.7. Quality control . . . . .</b>	<b>98</b>
<b>2.8. Quarantine and release . . . . .</b>	<b>98</b>
<b>2.9. Validation and qualification . . . . .</b>	<b>98</b>
2.9.1. Qualification of facilities and equipment . . . . .	99
2.9.2. General principles of process validation . . . . .	100
2.9.3. Planning for validation. . . . .	101
2.9.4. Validation documentation. . . . .	101
2.9.5. Prospective validation. . . . .	101
<b>2.10. Change control. . . . .</b>	<b>102</b>
<b>2.11. Traceability. . . . .</b>	<b>102</b>
<b>2.12. Complaints . . . . .</b>	<b>103</b>
<b>2.13. Investigation and reporting of non-conformance, adverse events and adverse reactions . . . . .</b>	<b>103</b>

---

2.14. Recall . . . . .	104
2.15. Self-assessment, internal audit and external audit . . . . .	104
2.16. Quality risk management . . . . .	105
2.17. Continuity planning . . . . .	108
2.18. References . . . . .	108
<b>Chapter 3 Recruitment of potential donors, identification and consent . . . . .</b>	<b>109</b>
3.1. Introduction . . . . .	109
3.2. Living donors . . . . .	110
3.2.1. Donor recruitment . . . . .	110
3.2.2. Consent/authorisation of donors . . . . .	113
3.3. The deceased donor . . . . .	114
3.3.1. Donor detection . . . . .	115
3.3.2. Consent/authorisation for deceased donation . . . . .	115
3.4. Data protection and confidentiality . . . . .	117
<b>Chapter 4 Donor evaluation . . . . .</b>	<b>119</b>
4.1. Introduction . . . . .	119
4.2. Donor information . . . . .	120
4.2.1. Evaluation of medical history (generic- and tissue-specific contraindications) . . . . .	122
4.2.2. Evaluation of behavioural risk . . . . .	128
4.3. ‘Hot topics’ . . . . .	131
4.3.1. Malignancy . . . . .	131
4.3.2. Epidemiological data used to assess sexual-risk behaviours, tattoos, and incarceration . . . . .	135
4.3.3. Transplantation with xenografts . . . . .	135
4.4. Physical evaluation of donors . . . . .	136
4.5. Additional information . . . . .	138
4.6. Considerations for evaluation of paediatric donors . . . . .	139
4.7. References . . . . .	139
<b>Chapter 5 Donor testing . . . . .</b>	<b>143</b>
5.1. Introduction . . . . .	143
5.2. General concepts . . . . .	144
5.3. Quality of donor samples . . . . .	144

5.3.1. Sample collection (sample type, tubes, labelling, time-limits and handling) .....	145
5.3.2. Haemodilution assessment. ....	148
5.4. Testing laboratories. ....	150
5.5. Tests to be carried out. ....	151
5.5.1. Additional tests .....	152
5.5.2. Re-tests of samples from living donors (allogeneic use) ...	154
5.5.3. Testing of autologous samples .....	154
5.6. Reporting and documentation of test results. ....	155
5.7. Archived samples .....	156
5.8. References .....	156
<b>Chapter 6 Procurement</b> .....	159
6.1. Introduction .....	159
6.2. Personnel. ....	160
6.3. Facilities, equipment and materials .....	161
6.3.1. Facilities. ....	161
6.3.2. Equipment and materials .....	168
6.4. Procedures .....	169
6.4.1. Temporary storage and transport. ....	172
6.5. Documentation .....	173
<b>Chapter 7 Processing and storage</b> .....	177
7.1. Introduction .....	177
7.2. Acceptance criteria (receipt at the tissue establishment) .....	178
7.3. Coding .....	180
7.4. Processing .....	181
7.4.1. General .....	181
7.4.2. Processing methods .....	183
7.4.3. Processing validation .....	184
7.4.4. Requirements of processing facilities. ....	186
7.4.5. Selecting the appropriate air quality for processing .....	189
7.4.6. Environmental airborne monitoring. ....	191
7.4.7. Environmental microbiological monitoring. ....	196
7.4.8. Cleaning .....	199
7.4.9. Avoiding contamination and cross-contamination. ....	201



---

7.5. Quality control	204
7.5.1. General	204
7.5.2. Microbiological control	204
7.6. Packaging and labelling	205
7.7. Storage	205
7.7.1. Methods of storage	205
7.7.2. Expiry date	207
7.7.3. Risk assessment	207
7.7.4. Storage temperature	208
7.7.5. Cross-contamination during storage	208
7.7.6. Quarantine	209
7.8. Release	209
7.8.1. Release procedure	209
7.8.2. Exceptional release	211
7.8.3. Disposal of human tissues and cells	212
7.9. References	212
<b>Chapter 8 Principles of microbiological testing</b>	<b>215</b>
8.1. Introduction	215
8.2. Microbiological examination of donors: blood cultures	216
8.3. General considerations for microbiological control of human tissues and cells	217
8.3.1. Microbiological concepts for the detection of bacteria and fungi	218
8.3.2. Testing for micro-organisms with specific growth requirements	220
8.3.3. Testing for bacterial endotoxins	221
8.3.4. Explanatory notes – microbial controls required for specific processing methods	223
8.4. Microbiological testing	225
8.4.1. Sterility testing of solutions or tissue samples pursuant to <i>Ph. Eur.</i> 2.6.1	225
8.4.2. Microbiological testing using automated culture systems ( <i>Ph. Eur.</i> 2.6.27)	227
8.5. Notes on the validation of microbiological methods for the testing of preparations of tissues and cells	229

8.5.1. Growth promotion test . . . . .	229
8.5.2. Method validation . . . . .	230
8.5.3. Documentation and interpretation of results . . . . .	232
<b>8.6. Interpretation of results and actions to be taken. . . . .</b>	<b>232</b>
<b>8.7. General considerations for microbiological monitoring of the environment and reagents . . . . .</b>	<b>234</b>
8.7.1. Incubation of samples . . . . .	236
8.7.2. Data analyses . . . . .	236
<b>8.8. References . . . . .</b>	<b>236</b>
<b>Chapter 9 Distribution and import/export . . . . .</b>	<b>239</b>
<b>9.1. Introduction . . . . .</b>	<b>239</b>
<b>9.2. Transport . . . . .</b>	<b>240</b>
<b>9.3. Allocation . . . . .</b>	<b>241</b>
9.3.1. Visual examination . . . . .	241
9.3.2. Medical competence . . . . .	241
9.3.3. Documentation . . . . .	241
9.3.4. Recall and return procedures . . . . .	242
<b>9.4. Import and export. . . . .</b>	<b>242</b>
9.4.1. Underlying principles . . . . .	242
9.4.2. Import. . . . .	243
9.4.3. Customs clearance . . . . .	245
9.4.4. Acceptance at the establishment . . . . .	246
9.4.5. EU requirements for importing tissues and cells. . . . .	246
9.4.6. Export. . . . .	247
<b>9.5. International co-operation . . . . .</b>	<b>248</b>
<b>Chapter 10 Organisations responsible for human application . .</b>	<b>249</b>
<b>10.1. Introduction . . . . .</b>	<b>249</b>
<b>10.2. Appropriate use . . . . .</b>	<b>249</b>
<b>10.3. Choosing a supplier of tissues or cells . . . . .</b>	<b>250</b>
<b>10.4. Receiving tissues or cells from other countries. . . . .</b>	<b>253</b>
<b>10.5. Exceptional release . . . . .</b>	<b>253</b>
<b>10.6. Recipient consent. . . . .</b>	<b>254</b>
<b>10.7. Centralised <i>versus</i> decentralised management of tissues and cells . . . . .</b>	<b>255</b>

---

10.8. Incoming inspection at the organisation responsible for human application .....	256
10.9. Package insert/instructions and temporary storage before use .....	257
10.10. Inspection of the container, documentation and tissues or cells.....	258
10.11. Preparation of tissues or cells before use .....	258
10.12. Surplus or unused tissues or cells.....	259
10.13. Traceability .....	259
10.14. Adverse events and adverse reactions .....	261
10.15. Management of recalls and reviews .....	262
10.16. References .....	263
<b>Chapter 11 Computerised systems .....</b>	<b>265</b>
11.1. Introduction .....	265
11.2. Planning the implementation of a computerised system. . .	266
11.3. Qualification and testing .....	267
11.4. Change control .....	272
11.5. Maintenance of the system.....	272
11.6. Quality assurance .....	273
11.7. Industry guidance for validation of the computerised system .....	273
11.8. Regulations governing validation of computerised systems in Good Manufacturing Practices .....	274
11.9. Infrastructure.....	276
11.10. Failure of the system.....	276
11.11. Electronic signature .....	276
11.12. Data protection .....	276
11.13. Archiving.....	277
11.14. References .....	277
<b>Chapter 12 Packaging and labelling .....</b>	<b>279</b>
12.1. Introduction .....	279
12.2. General concepts .....	280
12.3. Packaging of tissues and cells .....	281
12.4. Labelling of tissues and cells.....	281

12.5. Sample and documentation labelling . . . . .	283
12.6. Management of packaging and labelling materials . . . . .	283
12.7. Primary packaging and labelling for procurement operations . . . . .	284
12.8. Secondary packaging and labelling for procurement operations . . . . .	286
12.9. Outer container packaging and labelling for procurement operations . . . . .	286
12.10. Procurement package insert . . . . .	287
12.11. Packaging and labelling during processing . . . . .	288
12.12. Primary packaging and labelling for finished tissues and cells . . . . .	288
12.13. Secondary packaging and labelling for finished tissues and cells . . . . .	290
12.14. Outer container packaging and labelling for finished tissues and cells. . . . .	290
12.15. Package insert for finished tissues and cells . . . . .	291
12.16. Customs clearance. . . . .	292
12.17. References . . . . .	293
<b>Chapter 13 Traceability . . . . .</b>	<b>295</b>
13.1. Introduction . . . . .	295
13.2. What is traceability? . . . . .	297
13.3. Which records must be traceable? . . . . .	299
13.3.1. Records of identification, donor tests and clinical evaluation of the donor . . . . .	300
13.3.2. Records of procurement of tissues and cells . . . . .	301
13.3.3. Records of processing of tissues . . . . .	302
13.3.4. Records of storage and distribution of tissues and cells . . . . .	302
13.3.5. Records of end use of tissues and cells . . . . .	303
13.4. Single European Code for tissues and cells . . . . .	304
13.4.1. Tools for implementation of the Single European Code . . . . .	305
13.4.2. Structure and format of the Single European Code. . . . .	306
13.4.3. Application of the Single European Code . . . . .	307
13.5. References . . . . .	308

---

<b>Chapter 14 Biovigilance</b> .....	311
14.1. Introduction .....	311
14.2. Management and quality .....	313
14.2.1. Non-serious adverse events and reactions .....	314
14.2.2. Complaints .....	314
14.3. Adverse reactions .....	315
14.3.1. Detection of adverse reactions .....	316
14.3.2. Reporting adverse reactions .....	318
14.3.3. Investigation and assessment of adverse reactions .....	323
14.4. Adverse events .....	326
14.4.1. Detection of serious adverse events .....	326
14.4.2. Serious adverse event reporting .....	326
14.4.3. Investigation and assessment of adverse events .....	327
14.5. Vigilance co-ordination .....	327
14.5.1. Rapid alerts .....	327
14.6. Vigilance communication .....	328
14.6.1. 'No blame' culture .....	328
14.6.2. Vigilance experience and feedback .....	329
14.7. Surveillance for new risks .....	329
14.8. References .....	330
<b>PART B. SPECIFIC REQUIREMENTS</b> .....	333
<b>Chapter 15 Ocular tissue</b> .....	335
15.1. Introduction .....	335
15.2. Donor evaluation .....	337
15.2.1. Exclusion criteria for cornea donation .....	337
15.2.2. Exclusion criteria for other types of ocular tissue donation (e.g. sclera, limbal tissue, limbal cells) .....	338
15.3. Procurement .....	338
15.3.1. <i>Post mortem</i> time .....	338
15.3.2. Procurement team .....	339
15.3.3. Procurement procedure .....	339
15.3.4. Reconstruction of the donor .....	340
15.4. Receipt of procured tissue at tissue establishments .....	340
15.5. Processing and storage .....	340

15.5.1. Processing facilities . . . . .	340
15.5.2. Cornea processing methods . . . . .	341
15.5.3. Cornea storage methods . . . . .	342
15.5.4. Sclera processing and storage. . . . .	343
<b>15.6. Microbiological testing of the storage medium . . . . .</b>	<b>344</b>
<b>15.7. Quality control and cornea evaluation . . . . .</b>	<b>344</b>
<b>15.8. Examples of serious adverse reactions and serious adverse events . . . . .</b>	<b>346</b>
<b>15.9. References . . . . .</b>	<b>347</b>
<b>Chapter 16 Amniotic membrane . . . . .</b>	<b>349</b>
<b>16.1. Introduction . . . . .</b>	<b>349</b>
<b>16.2. Donor evaluation. . . . .</b>	<b>350</b>
16.2.1. Specific exclusion criteria . . . . .	351
<b>16.3. Procurement . . . . .</b>	<b>351</b>
16.3.1. Procurement facility and procurement team. . . . .	351
16.3.2. Storage and transport after procurement. . . . .	351
<b>16.4. Processing and storage. . . . .</b>	<b>352</b>
16.4.1. Receipt of procured placenta at the tissue establishment .	352
16.4.2. Processing facilities. . . . .	353
16.4.3. Processing methods. . . . .	354
<b>16.5. Quality control. . . . .</b>	<b>356</b>
<b>16.6. Distribution . . . . .</b>	<b>356</b>
<b>16.7. References . . . . .</b>	<b>357</b>
<b>Chapter 17 Skin. . . . .</b>	<b>359</b>
<b>17.1. Introduction . . . . .</b>	<b>359</b>
<b>17.2. Skin-specific donor evaluation . . . . .</b>	<b>361</b>
17.2.1. Skin inspection . . . . .	361
17.2.2. Skin-specific exclusion criteria. . . . .	361
17.2.3. Skin-specific procurement procedures . . . . .	362
17.2.4. Skin-specific <i>post mortem</i> time . . . . .	362
<b>17.3. Skin procurement. . . . .</b>	<b>362</b>
17.3.1. Skin-specific procurement team. . . . .	362
17.3.2. Skin procurement procedure . . . . .	363
17.3.3. Reconstruction of the skin donor. . . . .	363

17.3.4. Procurement documentation . . . . .	364
17.3.5. Skin transportation to the tissue establishment . . . . .	364
17.3.6. Receipt of procured skin at the tissue establishment . . . . .	364
<b>17.4. Skin processing . . . . .</b>	<b>364</b>
17.4.1. Processing facilities . . . . .	366
17.4.2. Skin decontamination and preservation . . . . .	366
17.4.3. Skin graft sizing . . . . .	367
17.4.4. Glycerol-preserved skin allografts . . . . .	367
17.4.5. Fresh skin allografts. . . . .	367
17.4.6. Cryopreserved skin allografts . . . . .	368
17.4.7. Lyophilised skin allografts . . . . .	368
17.4.8. De-epidermised dermis and acellular dermis . . . . .	368
17.4.9. Sterilisation of skin allografts . . . . .	369
<b>17.5. Quality control . . . . .</b>	<b>369</b>
17.5.1. Microbiological testing of skin . . . . .	369
17.5.2. Skin allograft distribution. . . . .	370
<b>17.6. Examples of serious adverse reactions and serious adverse events . . . . .</b>	<b>370</b>
<b>17.7. References . . . . .</b>	<b>371</b>
<b>Chapter 18 Cardiovascular tissue . . . . .</b>	<b>373</b>
<b>18.1. Introduction . . . . .</b>	<b>373</b>
<b>18.2. Donor evaluation. . . . .</b>	<b>375</b>
18.2.1. Contraindications specific for cardiovascular tissue . . . . .	375
<b>18.3. Procurement . . . . .</b>	<b>375</b>
18.3.1. Procurement team . . . . .	375
18.3.2. Procurement procedure . . . . .	376
18.3.3. Tissue transportation to the tissue establishment. . . . .	376
18.3.4. Procurement documentation. . . . .	376
<b>18.4. Processing and storage. . . . .</b>	<b>376</b>
18.4.1. Decellularisation of cardiovascular tissues . . . . .	377
18.4.2. Processing facilities. . . . .	378
<b>18.5. Cryopreservation and storage in liquid nitrogen . . . . .</b>	<b>379</b>
<b>18.6. Cardiovascular tissue thawing . . . . .</b>	<b>379</b>
<b>18.7. Quality control . . . . .</b>	<b>380</b>
<b>18.8. Cardiovascular allograft distribution . . . . .</b>	<b>382</b>

<b>18.9. Examples of serious adverse reactions and serious adverse events</b> .....	383
<b>Chapter 19 Musculoskeletal tissue</b> .....	385
<b>19.1. Introduction</b> .....	385
<b>19.2. Donor evaluation requirements</b> .....	387
19.2.1. Physical evaluation. ....	387
19.2.2. Specific contraindications for musculoskeletal tissue ...	388
19.2.3. Age limits for donors. ....	388
<b>19.3. Procurement</b> .....	388
19.3.1. Time limits for procurement .....	389
19.3.2. Procurement from deceased donors .....	389
19.3.3. Reconstruction of the deceased donor .....	390
19.3.4. Procurement from living donors. ....	390
<b>19.4. Processing</b> .....	391
19.4.1. Processing facilities .....	391
19.4.2. Musculoskeletal graft processing .....	393
19.4.3. Impact of processing on musculoskeletal allografts ....	394
19.4.4. Sterilisation or decontamination of musculoskeletal tissues and cells. ....	395
<b>19.5. Packaging and labelling</b> .....	397
<b>19.6. Transport and storage.</b> .....	397
19.6.1. Transport of musculoskeletal tissues .....	397
19.6.2. Storage of musculoskeletal tissues .....	398
<b>19.7. Quality control</b> .....	399
<b>19.8. Examples of serious adverse reactions and serious adverse events</b> .....	400
<b>19.9. References</b> .....	401
<b>Chapter 20 General considerations for cell-based therapies</b> ....	403
<b>20.1. Introduction</b> .....	403
<b>20.2. EU legal framework</b> .....	405
20.2.1. Advanced Therapy Medicinal Products Regulation ....	405
20.2.2. National Competent Authorities .....	407
20.2.3. Ethics Committees .....	408
<b>20.3. Processing cells for human application.</b> .....	409



---

20.3.1. Special safety considerations when culturing cells . . . . .	409
20.3.2. Microbiological testing when culturing cells . . . . .	411
20.3.3. Considerations for quality control . . . . .	413
20.3.4. Master cell banks and working cell banks . . . . .	414
20.3.5. Safety considerations when applying cells to patients . . .	415
<b>20.4. Genetic modifications of cells. . . . .</b>	<b>416</b>
<b>20.5. Natural scaffolds for clinical use . . . . .</b>	<b>417</b>
20.5.1. Donor selection and procurement . . . . .	418
20.5.2. Decellularisation agents . . . . .	418
20.5.3. Considerations for choosing the appropriate decellularisation agent. . . . .	419
20.5.4. Quality controls. . . . .	423
20.5.5. Sterilisation of natural scaffolds . . . . .	423
20.5.6. Packaging and distribution . . . . .	424
<b>20.6. References . . . . .</b>	<b>424</b>
<b>Chapter 21 Haematopoietic stem cells . . . . .</b>	<b>427</b>
<b>21.1. Introduction . . . . .</b>	<b>427</b>
<b>21.2. Donor evaluation. . . . .</b>	<b>429</b>
21.2.1. Specific considerations for paediatric donors . . . . .	432
<b>21.3. Collection . . . . .</b>	<b>433</b>
21.3.1. Bone marrow. . . . .	434
21.3.2. Peripheral blood . . . . .	435
21.3.3. Cord blood. . . . .	438
<b>21.4. Processing . . . . .</b>	<b>440</b>
21.4.1. Volume reduction. . . . .	441
21.4.2. Red blood cell depletion . . . . .	442
21.4.3. Plasma removal . . . . .	442
21.4.4. Cryopreservation, thawing and infusion . . . . .	442
21.4.5. Cell selected preparations. . . . .	444
21.4.6. Depletion of allo-reactive immune effectors. . . . .	445
21.4.7. Immunocompetent cells used after haematopoietic stem cell transplantation . . . . .	446
<b>21.5. Quality control . . . . .</b>	<b>447</b>
21.5.1. Biological information needed to confirm donor suitability and recruitment. . . . .	447

21.5.2. Safety controls . . . . .	447
21.5.3. Quality controls (including potency assays and markers)	448
21.5.4. Release criteria . . . . .	449
21.6. Storage . . . . .	450
21.7. Packaging and labelling . . . . .	451
21.8. Vigilance and surveillance . . . . .	451
21.8.1. Serious adverse reactions in the recipient . . . . .	452
21.8.2. Serious product adverse events/reactions . . . . .	460
21.8.3. Serious adverse reactions in haematopoietic stem cell donors. . . . .	461
21.9. References . . . . .	462
<b>Chapter 22 Other cells . . . . .</b>	<b>465</b>
22.1. Introduction . . . . .	465
22.2. Important notice for tissue establishments and other operators established in the EU. . . . .	466
22.3. Allogeneic mononuclear cells (donor lymphocyte infusions) . . . . .	467
22.3.1. Donor selection . . . . .	467
22.3.2. Procurement. . . . .	467
22.3.3. Processing . . . . .	468
22.3.4. Quality control. . . . .	468
22.3.5. Storage . . . . .	468
22.3.6. Biovigilance . . . . .	468
22.4. Virus specific T-cells. . . . .	469
22.4.1. Procurement. . . . .	469
22.4.2. Processing . . . . .	469
22.4.3. Quality control. . . . .	470
22.4.4. Storage and distribution . . . . .	471
22.4.5. Biovigilance/pharmacovigilance . . . . .	471
22.5. Keratinocytes . . . . .	471
22.5.1. General introduction. . . . .	471
22.5.2. Donor selection . . . . .	473
22.5.3. Procurement . . . . .	473
22.5.4. Processing and storage . . . . .	474
22.5.5. Quality controls/release criteria . . . . .	476

22.5.6. Packaging and distribution . . . . .	476
22.5.7. Traceability . . . . .	477
22.5.8. Biovigilance/pharmacovigilance. . . . .	477
<b>22.6. Dendritic cells . . . . .</b>	<b>477</b>
22.6.1. General introduction . . . . .	477
22.6.2. Donor selection . . . . .	477
22.6.3. Procurement. . . . .	478
22.6.4. Processing and storage. . . . .	478
22.6.5. Quality controls/release criteria . . . . .	478
22.6.6. Packaging and distribution . . . . .	479
22.6.7. Traceability . . . . .	479
22.6.8. Biovigilance/pharmacovigilance . . . . .	479
<b>22.7. Chondrocytes . . . . .</b>	<b>479</b>
22.7.1. Donor selection. . . . .	480
22.7.2. Procurement. . . . .	480
22.7.3. Processing and storage . . . . .	481
22.7.4. Quality controls/release criteria . . . . .	482
22.7.5. Packaging and distribution . . . . .	483
22.7.6. Traceability . . . . .	484
22.7.7. Biovigilance/pharmacovigilance . . . . .	484
<b>22.8. Hepatocytes . . . . .</b>	<b>484</b>
22.8.1. Donor selection . . . . .	485
22.8.2. Procurement. . . . .	486
22.8.3. Transportation of liver tissue to the processing establishment . . . . .	486
22.8.4. Processing and storage. . . . .	487
22.8.5. Cryopreservation, storage, and thawing of hepatocytes .	487
22.8.6. Quality controls/release criteria . . . . .	488
22.8.7. Packaging and distribution . . . . .	489
22.8.8. Traceability. . . . .	489
22.8.9. Biovigilance . . . . .	489
<b>22.9. Natural killer cells . . . . .</b>	<b>489</b>
22.9.1. General introduction. . . . .	490
22.9.2. Donor selection . . . . .	491
22.9.3. Procurement. . . . .	491

22.9.4. Processing and storage . . . . .	491
22.9.5. Quality controls/release criteria . . . . .	492
22.9.6. Packaging and distribution . . . . .	492
22.9.7. Traceability . . . . .	492
22.9.8. Biovigilance/Pharmacovigilance . . . . .	492
<b>22.10. Pancreatic islet cells . . . . .</b>	<b>493</b>
22.10.1. General introduction. . . . .	493
22.10.2. Donor selection . . . . .	494
22.10.3. Procurement . . . . .	494
22.10.4. Processing and storage . . . . .	494
22.10.5. Quality controls/release criteria . . . . .	494
22.10.6. Packaging and distribution . . . . .	495
22.10.7. Traceability . . . . .	495
22.10.8. Biovigilance . . . . .	495
<b>22.11. Mesenchymal stem cells . . . . .</b>	<b>495</b>
22.11.1. Donor selection . . . . .	497
22.11.2. Procurement . . . . .	498
22.11.3. Processing and storage. . . . .	498
22.11.4. Quality controls/release criteria . . . . .	500
22.11.5. Packaging and distribution. . . . .	500
22.11.6. Traceability . . . . .	500
22.11.7. Biovigilance/pharmacovigilance . . . . .	500
<b>22.12. Limbal stem cells (ocular surface) . . . . .</b>	<b>501</b>
22.12.1. General introduction. . . . .	501
22.12.2. Donor and tissue selection. . . . .	502
22.12.3. Procurement . . . . .	502
22.12.4. Processing tissue and storage . . . . .	503
22.12.5. Quality controls and release criteria. . . . .	504
22.12.6. Packaging and distribution . . . . .	504
22.12.7. Traceability . . . . .	505
22.12.8. Biovigilance/pharmacovigilance . . . . .	505
<b>22.13. References . . . . .</b>	<b>505</b>
<b>Chapter 23 Adipose tissue . . . . .</b>	<b>511</b>

---

<b>Chapter 24 Other substances of human origin for clinical application</b> .....	513
24.1. Introduction .....	513
24.2. Breast milk .....	514
24.3. Faecal microbiota .....	516
24.4. Teeth and dental pulp .....	518
24.5. Platelet-rich plasma and platelet-rich fibrin .....	518
24.6. Serum eye drops .....	519
24.7. References .....	520
<b>Chapter 25 Assisted reproductive technology</b> .....	525
25.1. Introduction .....	525
25.2. Consent .....	528
25.3. Donor evaluation .....	530
25.3.1. Evaluation of partner donors .....	530
25.3.2. Evaluation of non-partner donors .....	533
25.4. Testing .....	535
25.4.1. Testing in partner donation .....	535
25.4.2. Testing in non-partner donation .....	536
25.5. Collection .....	537
25.5.1. Sperm .....	537
25.5.2. Oocytes .....	539
25.5.3. Ovarian tissue .....	540
25.6. Processing .....	540
25.6.1. Facilities for processing of gametes and embryos .....	540
25.6.2. Handling of gametes and embryos .....	541
25.6.3. Insemination of oocytes .....	544
25.6.4. Assessment of fertilisation .....	544
25.6.5. Embryo culture and transfer .....	545
25.6.6. Pre-implantation genetic diagnosis and pre-implantation genetic screening .....	546
25.6.7. <i>In vitro</i> maturation .....	547
25.6.8. Processing of samples from seropositive donors .....	547
25.7. Cryopreservation and storage .....	548
25.7.1. Methods for cryopreservation of human gametes and embryos .....	548

<b>25.8. Storage</b> .....	550
25.8.1. Storage limits .....	550
25.8.2. Storage temperature .....	550
25.8.3. Storage devices .....	551
25.8.4. Cross-contamination during storage.....	551
25.8.5. Storage safety .....	552
<b>25.9. Packaging and labelling in assisted reproductive technologies.</b> .....	552
<b>25.10. Vigilance in assisted reproductive technologies</b> .....	552
25.10.1. General criteria for reporting serious adverse reactions and events in assisted reproduction technologies .....	553
25.10.2. Transmission of genetic diseases by assisted reproductive technologies with non-partner donations .....	555
25.10.3. Examples of serious adverse reactions and events in assisted reproduction technologies .....	555
25.10.4. Cross-border management of serious adverse reactions and events .....	556
<b>25.11. Final considerations</b> .....	556
<b>25.12. References</b> .....	557
<b>Chapter 26 Fertility preservation.</b> .....	561
<b>Appendix 1 General reference documents used</b> .....	565
<b>Appendix 2 Acronyms</b> .....	573
<b>Appendix 3 Glossary</b> .....	583
<b>Appendix 4 Sample consent form</b> .....	609
<b>Appendix 5 Sample donor assessment form.</b> .....	617
<b>Appendix 6 Sample tissue donor physical assessment form.</b> ....	651
<b>Appendix 7 Sample haemodilution algorithm</b> .....	655
<b>Appendix 8 Validation of screening for infectious disease assays for use with blood from deceased donors.</b> .....	657
<b>Appendix 9 Sample form to assess the suitability of the working environment</b> .....	663

---

<b>Appendix 10</b>	<b>Sample donor identification form</b> . . . . .	665
<b>Appendix 11</b>	<b>Example of a process validation</b> . . . . .	667
<b>Appendix 12</b>	<b>Adverse reaction or event impact assessment tool</b> .	671
<b>Appendix 13</b>	<b>Summary of data reported in the 2011 EU-wide report of serious adverse reactions and serious adverse events associated with the clinical application of tissues and cells (data reported for 2010)</b> . . . . .	675
<b>Appendix 14</b>	<b>Members of the <i>ad hoc</i> working groups (TO055 and TO056) for the elaboration of the 2<sup>nd</sup> edition of the Guide to the quality and safety of tissues and cells for human application</b>	679
<b>Appendix 15</b>	<b>Members of the European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO)</b> . . . . .	687